The top 14 highest-paid biopharma CEOs of 2019
FiercePharma‘s list of highest-paid biopharma CEOs includes both midsized companies and some of the industry’s largest drugmakers. U.S. companies dominated the list, and CEOs at midsize biotechs outearned their counterparts at some of the world’s biggest companies. See which CEOs made the list, as ranked by their 2019 total pay:
- Martine Rothblatt, United Therapeutics – $45.64M
- Daniel O’Day, Gilead Sciences – $29.11M
- Kenneth Frazier, Merck & Co. – $27.65M
- Alex Gorsky, Johnson & Johnson – $25.37M
- Richard Gonzalez, AbbVie – $21.61M
- David Ricks, Eli Lilly – $21.28M
- Robert Bradway, Amgen – $19.6M
- Ludwig Hantson, Alexion Pharmaceuticals – $18.95M
- Giovanni Caforio, Bristol Myers Squibb – $18.8M
- Jeffrey Leiden, Vertex Pharmaceuticals – $18.79M
- Heather Bresch, Mylan – $18.5M
- Pascal Soriot, AstraZeneca – $18.30M
- Michel Vounatsos, Biogen – $18.16M
- Albert Bourla, Pfizer – $17.92M
